JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
AstraZeneca, Sinopharm and Moderna were part of the study
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
